Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Merck & Co., Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--MERCK ANNOUNCES POSITIVE NEW DATA FOR ENFLONSIA (CLESROVIMAB) FOR INFANTS AND CHILDREN UNDER 2 AT INCREASED RISK FOR SEVERE RSV OVER TWO RSV SEASONS.

MERCK ANNOUNCES POSITIVE NEW DATA FOR ENFLONSIA (CLESROVIMAB) FOR INFANTS AND CHILDREN UNDER 2 YEARS OF AGE AT INCREASED RISK FOR SEVERE RESPIRATORY SYNCYTIAL VIRUS (RSV) DISEASE OVER TWO RSV SEASONS

RAHWAY, N.J., & ROCHESTER, MINN.--(BUSINESS WIRE)--MERCK AND MAYO CLINIC TODAY ANNOUNCED A R&D AGREEMENT TO APPLY ARTIFICIAL INTELLIGENCE (AI), ADVANCED ANALYTICS AND DATA TO SUPPORT DRUG DISCOVERY.

MERCK AND MAYO CLINIC ANNOUNCE NEW RESEARCH AND DEVELOPMENT COLLABORATION TO SUPPORT AI-ENABLED DRUG DISCOVERY AND PRECISION MEDICINE

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--MERCK ADVANCES TREATMENT OF BLADDER AND KIDNEY CANCERS WITH NEW DATA AT 2026 ASCO GU CANCERS SYMPOSIUM.

MERCK ADVANCES TREATMENT OF BLADDER AND KIDNEY CANCERS WITH NEW DATA AT 2026 ASCO GU CANCERS SYMPOSIUM

RAHWAY, N.J.--(BUSINESS WIRE)--MERCK (NYSE: MRK), KNOWN AS MSD OUTSIDE OF THE UNITED STATES AND CANADA, TODAY ANNOUNCED THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVED KEYTRUDA (PEMBROLIZUMAB) AND KEYTRUDA QLEX (PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH) PLUS PACLITAXEL, WITH OR WITHOUT BEVACIZUMAB, FOR THE TREATMENT OF ADULTS WITH PD-L1+ (COMBINED POSITIVE SCORE [CPS] 1), AS DETERMINED BY AN FDA-AUTHORIZED TEST, PLATINUM-RESISTANT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERIT.

KEYTRUDA (PEMBROLIZUMAB) AND KEYTRUDA QLEX (PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH), PLUS PACLITAXEL  BEVACIZUMAB, APPROVED FOR CERTAIN ADULTS WITH PD-L1+ (CPS 1) PLATINUM-RESISTANT OVARIAN CARCINOMA AS SECOND OR THIRD LINE TREATMENT

LONDON--(BUSINESS WIRE)--CALLA LILY CLINICAL CARE, A WOMEN'S HEALTH-FOCUSED MEDICAL TECHNOLOGY COMPANY, AND MERCK, A LEADING SCIENCE AND TECHNOLOGY COMPANY, HAVE ENTERED A STRATEGIC COLLABORATION TO SUPPORT THE CONTINUED DEVELOPMENT OF CALLAVID, A NOVEL PLATFORM FOR INTRAVAGINAL DRUG DELIVERY. THE COLLABORATION REPRESENTS THE FIRST INDUSTRY PARTNERSHIP FOR THE CALLAVID TECHNOLOGY. CALLAVID IS A TRANSFORMATIONAL LEAK-RESISTANT MEDICAL DEVICE DESIGNED TO ADDRESS CHALLENGES ASSOCIATED WITH THE SE.

CALLA LILY CLINICAL CARE AND MERCK ANNOUNCE STRATEGIC COLLABORATION TO ADVANCE INTRAVAGINAL DRUG DELIVERY PLATFORM

RAHWAY, N.J.--(BUSINESS WIRE)--MERCK & CO., INC., RAHWAY, N.J., USA ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS.

MERCK & CO., INC., RAHWAY, N.J., USA ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS; HIGHLIGHTS PROGRESS ADVANCING BROAD, DIVERSE PIPELINE

RAHWAY, N.J.--(BUSINESS WIRE)--MERCK ANNOUNCES SECOND-QUARTER 2026 DIVIDEND.

MERCK ANNOUNCES SECOND-QUARTER 2026 DIVIDEND

AT A MEDIAN FIVE-YEAR PRE-PLANNED FOLLOW-UP OF THE PHASE 2B KEYNOTE-942/MRNA-4157-P201 STUDY, INTISMERAN AUTOGENE IN COMBINATION WITH KEYTRUDA REDUCED THE RISK OF RECURRENCE OR DEATH BY 49% (HR=0.510; [95% CI, 0.294-0.887]) COMPARED TO KEYTRUDA ALONE THE COMPANIES PLAN TO PRESENT FURTHER DATA FROM FOLLOW UP ANALYSES OF THE STUDY'S PRIMARY AND SECONDARY ENDPOINTS AT A FUTURE MEDICAL CONFERENCE EIGHT PHASE 2 AND PHASE 3 CLINICAL TRIALS UNDERWAY ACROSS MULTIPLE TUMOR TYPES INCLUDING MELANOMA, NON-SMALL CELL LUNG CANCER, BLADDER CANCER AND RENAL CELL CARCINOMA CAMBRIDGE, MA AND RAHWAY, NJ / ACCESS NEWSWIRE / JANUARY 20, 2026 / MODERNA, INC. (NASDAQ:MRNA) AND MERCK (NYSE:MRK), KNOWN AS MSD OUTSIDE OF THE UNITED STATES AND CANADA, TODAY ANNOUNCED MEDIAN FIVE-YEAR FOLLOW-UP DATA FROM THE PHASE 2B KEYNOTE-942/MRNA-4157-P201 STUDY, EVALUATING INTISMERAN AUTOGENE (MRNA-4157 OR V940), AN INVESTIGATIONAL MRNA-BASED INDIVIDUALIZED NEOANTIGEN THERAPY (INT), IN COMBINATION WITH KEYTRUDA (PEMBROLIZUMAB), MERCK'S ANTI-PD-1 THERAPY, IN PATIENTS WITH HIGH-RISK MELANOMA (STAGE III/IV) FOLLOWING COMPLETE RESECTION. IN THIS PRE-PLANNED ANALYSIS, ADJUVANT TREATMENT WITH INTISMERAN AUTOGENE IN COMBINATION WITH KEYTRUDA CONTINUED TO DEMONSTRATE SUSTAINED AND CLINICALLY MEANINGFUL IMPROVEMENT IN THE STUDY'S PRIMARY ENDPOINT, RECURRENCE-FREE SURVIVAL (RFS), REDUCING THE RISK OF RECURRENCE OR DEATH BY 49% (HR=0.510; [95% CI, 0.294-0.887]; ONE-SIDED NOMINAL P=0.0075) COMPARED TO KEYTRUDA ALONE.

MODERNA & MERCK ANNOUNCE 5-YEAR DATA FOR INTISMERAN AUTOGENE IN COMBINATION WITH KEYTRUDA(R) (PEMBROLIZUMAB) DEMONSTRATED SUSTAINED IMPROVEMENT IN THE PRIMARY ENDPOINT OF RECURRENCE-FREE SURVIVAL IN PATIENTS WITH HIGH-RISK STAGE III/IV MELANOMA FOLLOWING COMPLETE RESECTION

DUBAI, UNITED ARAB EMIRATES--(BUSINESS WIRE)-- #100MOSTINFLUENTIALAFRICANS--DR. RASHA KELEJ, CEO OF MERCK FOUNDATION, HAS BEEN RECOGNIZED AS ONE OF THE 100 MOST INFLUENTIAL AFRICANS BY NEW AFRICAN MAGAZINE (UK).

DR. RASHA KELEJ, CEO OF MERCK FOUNDATION, NAMED ONE OF 100 MOST INFLUENTIAL AFRICANS 2025' ALONGSIDE PRESIDENTS OF ANGOLA, SOUTH AFRICA, AND GHANA BY NEW AFRICAN MAGAZINE, UK

BRISBANE, AUSTRALIA AND CAMBRIDGE, MASS., JAN. 07, 2026 (GLOBE NEWSWIRE) -- VAXXAS PTY LTD TODAY ANNOUNCED THE APPOINTMENT OF GLOBAL BIOPHARMACEUTICAL EXECUTIVE MR DAVID PEACOCK AS CHIEF EXECUTIVE OFFICER TO LEAD THE COMMERCIALISATION OF THE COMPANY'S PROPRIETARY HIGHDENSITY MICROARRAY PATCH (HDMAP) VACCINATION TECHNOLOGY.

VAXXAS APPOINTS FORMER MERCK GLOBAL VACCINES PRESIDENT DAVID PEACOCK AS CEO

RAHWAY, N.J.--(BUSINESS WIRE)--MERCK TO COMPLETE ACQUISITION OF CIDARA THERAPEUTICS.

MERCK TO COMPLETE ACQUISITION OF CIDARA THERAPEUTICS

RAHWAY, N.J.--(BUSINESS WIRE)--MERCK TO HOLD FOURTH-QUARTER AND FULL-YEAR 2025 SALES AND EARNINGS CONFERENCE CALL FEB. 3.

MERCK TO HOLD FOURTH-QUARTER AND FULL-YEAR 2025 SALES AND EARNINGS CONFERENCE CALL FEB. 3

RAHWAY, N.J.--(BUSINESS WIRE)--MERCK TO PARTICIPATE IN THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE.

MERCK TO PARTICIPATE IN THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

RAHWAY, N.J.--(BUSINESS WIRE)--MERCK REACHES AGREEMENT WITH U.S. GOVERNMENT TO EXPAND ACCESS TO MEDICINES AND LOWER COSTS FOR AMERICANS.

MERCK REACHES AGREEMENT WITH U.S. GOVERNMENT TO EXPAND ACCESS TO MEDICINES AND LOWER COSTS FOR AMERICANS

RAHWAY, N.J.--(BUSINESS WIRE)--MERCK (NYSE: MRK), KNOWN AS MSD OUTSIDE THE UNITED STATES AND CANADA, TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM THE PHASE 3 KEYNOTE-B15 TRIAL (ALSO KNOWN AS EV-304) IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER (MIBC) WHO ARE ELIGIBLE FOR CISPLATIN-BASED CHEMOTHERAPY. THE TRIAL SHOWED KEYTRUDA (PEMBROLIZUMAB) PLUS PADCEV  (ENFORTUMAB VEDOTIN-EJFV), GIVEN AS NEOADJUVANT AND ADJUVANT TREATMENT (BEFORE AND AFTER SURGERY), DEMONSTRATED A STATISTICALLY SIGNIFIC.

KEYTRUDA (PEMBROLIZUMAB) PLUS PADCEV (ENFORTUMAB VEDOTIN-EJFV) SIGNIFICANTLY IMPROVED EVENT-FREE SURVIVAL, OVERALL SURVIVAL AND PATHOLOGIC COMPLETE RESPONSE RATES FOR CISPLATIN-ELIGIBLE PATIENTS WITH MIBC WHEN GIVEN BEFORE AND AFTER SURGERY

Merck & Co., Inc.

MRK

Price

Financial Reports

No items found.

Press Releases

Merck & Co., Inc.

MRK.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

MRK